https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2018 » October
Mereo BioPharma begins BPS-804 mid-stage trial in osteogenesis imperfecta

Mereo BioPharma begins BPS-804 mid-stage trial in osteogenesis imperfecta

British specialty biopharma company Mereo BioPharma Group has wrapped up enrollment of patients for a phase 2b clinical trial that will evaluate its human monoclonal antibody BPS-804 (Setrusumab) as a potential treatment option for osteogenesis imperfecta (OI), better known as the brittle bone disease. Osteogenesis imperfecta is a rare, chronic genetic disorder that makes bones […]

EC approves label update for Novartis psoriatic arthritis drug Cosentyx

The European Commission (EC) has approved a label update for Novartis psoriatic arthritis drug Cosentyx (secukinumab) to include dosing flexibility for treating the condition. Cosentyx is the first and only fully-human treatment that precisely prevents interleukin-17A (IL-17A), in psoriatic arthritis, which is a chronic, progressive and irreversible disease that causes pain, fatigue, and also activity […]

Continue reading …
Nordic Nanovector initiates mid-stage trial of Betalutin in 3L Follicular Lymphoma in US

Nordic Nanovector has opened its first clinical site in the US at Long Beach in California for the PARADIGME trial to evaluate its tumor-seeking anti-CD37 antibody Betalutin (lilotomab) in third-line (3L) follicular lymphoma. With the opening of the US clinical trial site, the Norwegian biopharma company has initiated the global randomized phase 2b trial of […]

Continue reading …
Galecto Biotech raises €79m to launch idiopathic pulmonary fibrosis trial

Galecto Biotech, a Denmark-based pharma company focused on developing galectin modulators for the treatment of severe diseases such as idiopathic pulmonary fibrosis and cancer, has raised €79 million through a series C financing round co-led by Ysios Capital and OrbiMed. New investors in Galecto Biotech are Ysios Capital, OrbiMed, HBM Healthcare Investments, Bristol Myers-Squibb, OrbiMed […]

Continue reading …
Alliqua to acquire San Francisco-based biopharma company Adynxx

Alliqua acquisition of Adynxx : Pennsylvania-based Alliqua BioMedical has agreed to merge with San Francisco-based biopharma company Adynxx to form a clinical-stage pharmaceutical firm focused on development of disease-modifying, non-opioid therapies for the treatment of pain. As per the merger terms, Adynxx stockholders will become the majority holders of Alliqua’s outstanding common stock on a […]

Continue reading …
Mylan launches Humira biosimilar Hulio across Europe

Mylan has launched Hulio, a biosimilar to AbbVie’s Humira (adalimumab), in major markets in Europe, a month after its approval from the European Commission for all indications of the reference product. Hulio will be available to patients as early as possible, said Mylan, which partnered with Fujifilm Kyowa Kirin Biologics in April to commercialize the […]

Continue reading …
TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa

TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of inherited Epidermolysis Bullosa (EB). The phase 2 trial of AC-203 is a double-blind, intra-individual comparison, proof-of-concept clinical trial and will feature patients as young as two years of age. The […]

Continue reading …
Sanofi, Regeneron report Dupixent FDA approval for asthma

Dupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the US Food and Drug Administration as an add-on maintenance therapy for two forms of asthma. Dupixent FDA Approval The new Dupixent FDA approval is for treating patients with moderate-to-severe asthma aged 12 years and older […]

Continue reading …
Novartis to acquire US biopharma company Endocyte for $2.1bn

Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its expertise in radiopharmaceuticals for the treatment of cancer. According to the merger terms, the Swiss pharma giant will buy all the shares of Endocyte at $24 per share. The US […]

Continue reading …
Quotient Sciences opens formulation, manufacturing facility in US near Philadelphia

Quotient Sciences, a UK-based drug development services provider, has expanded its operations in the US by opening an early phase formulation and manufacturing plant in Garnet Valley near Philadelphia. The new facility is of 45,000sft phase formulation and manufacturing plant has been built with an investment of $15 million. Quotient Sciences said that the expansion […]

Continue reading …
Page 1 of 212